Currently out of the existing stock ratings of Dana Flanders, 22 are a BUY (64.71%), 11 are a HOLD (32.35%), 1 are a SELL (2.94%).

Dana Flanders

Work Performance Price Targets & Ratings Chart

Analyst Dana Flanders, carries an average stock price target met ratio of 79.23% that have a potential upside of 20.75% achieved within 269 days. Previously, Dana Flanders worked at GOLDMAN SACHS.

Dana Flanders’s has documented 62 price targets and ratings displayed on 13 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on AMRX, Amneal Pharmaceuticals, Common Stock at 13-Apr-2021.

Wall Street Analyst Dana Flanders

Analyst best performing recommendations are on ANIP (ANI PHARMACEUTICALS).
The best stock recommendation documented was for ANIP (ANI PHARMACEUTICALS) at 9/11/2019. The price target of $76 was fulfilled within 2 days with a profit of $6.36 (9.13%) receiving and performance score of 45.66.

Average potential price target upside

of $11.31 (28.86%) on HZNP (HORIZON PHARMA PLC).
of $9.25 (14.3%) on EBS (EMERGENT BIOSOLUTIONS).
of $8.47 (13.17%) on ANIP (ANI PHARMACEUTICALS).

EBS Emergent Biosolutions HZNP Horizon Pharma PLC AMRX Amneal Pharmaceuticals, Common Stock BHC Bausch Health Companies BLU BELLUS Health ENDP Endo International PLC INSM Insmed PTLA Portola Pharmaceuticals PCRX Pacira Pharmaceuticals AKRX Akorn ANIP ANI Pharmaceuticals LCI Lannett Company MNTA Momenta Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Raghuram Selvaraju (HC WAINWRIGHT)